These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11804182)

  • 1. Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer.
    Airoldi M; Cattel L; Pedani F; Marchionatti S; Tagini V; Bumma C; Recalenda V
    Breast Cancer Res Treat; 2001 Dec; 70(3):185-95. PubMed ID: 11804182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
    Pagani O; Sessa C; Nolè F; Crivellari D; Lombardi D; Thürlimann B; Hess D; Borner M; Bauer J; Martinelli G; Graffeo R; Zucchetti M; D'Incalci M; Goldhirsch A
    Ann Oncol; 2000 Aug; 11(8):985-91. PubMed ID: 11038035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer.
    Airoldi M; Cattel L; Pedani F; Marchionatti S; Tagini V; Bumma C; Recalenda V
    Acta Oncol; 2003; 42(3):186-94. PubMed ID: 12852694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
    Viens P; Roché H; Kerbrat P; Fumoleau P; Guastalla JP; Delozier T
    Am J Clin Oncol; 2001 Aug; 24(4):328-35. PubMed ID: 11474255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).
    Kouroussis C; Xydakis E; Potamianou A; Giannakakis T; Kakolyris S; Agelaki S; Sara E; Malamos N; Alexopoulos A; Mavroudis D; Samonis G; Papadouris S; Georgoulias V; Panagos G
    Ann Oncol; 1999 May; 10(5):547-52. PubMed ID: 10416004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.
    Salminen E; Korpela J; Varpula M; Asola R; Varjo P; Pyrhönen S; Mali P; Hinkka S; Ekholm E
    Anticancer Drugs; 2002 Oct; 13(9):925-9. PubMed ID: 12394255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.
    Rischin D; Ackland SP; Smith J; Garg MB; Clarke S; Millward MJ; Toner GC; Zalcberg J
    Ann Oncol; 2002 Nov; 13(11):1810-8. PubMed ID: 12419756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
    Milla-Santos A; Milla L; Rallo L; Solano V
    Am J Clin Oncol; 2001 Apr; 24(2):138-42. PubMed ID: 11319287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel and epirubicin in advanced breast cancer.
    Sessa C; Pagani O
    Oncologist; 2001; 6 Suppl 3():13-6. PubMed ID: 11346679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
    Polyzos A; Tsavaris N; Kosmas C; Gogas H; Vadiaka M; Markopoulos C; Giannopoulos A; Kalahanis N; Stamatiadis D; Kouraklis G; Karatzas G; Liapis C; Syrigos K
    Anticancer Res; 2003; 23(3C):2917-23. PubMed ID: 12926135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study.
    Mavroudis D; Alexopoulos A; Ziras N; Malamos N; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Tsavaris N; Potamianou A; Rigatos G; Georgoulias V
    Ann Oncol; 2000 Oct; 11(10):1249-54. PubMed ID: 11106112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of anthracyclines and paclitaxel as first line chemotherapy in patients with visceral metastases of breast cancer.
    Rossi D; Graziano F; Luzi Fedeli S; Fedeli A; Alessandroni P; Catalano V; Giordani P; Testa E; Catalano G
    Minerva Med; 2002 Aug; 93(4):303-7. PubMed ID: 12207200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
    Mavroudis D; Saloustros E; Boukovinas I; Papakotoulas P; Kakolyris S; Ziras N; Christophylakis C; Kentepozidis N; Fountzilas G; Rigas G; Varthalitis I; Kalbakis K; Agelaki S; Hatzidaki D; Georgoulias V
    Br J Cancer; 2017 Jul; 117(2):164-170. PubMed ID: 28641315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
    Yeo W; Mok TS; Tse KK; Kwan WH; Lam KC; Ho WM; Chiu SK; Chan AT; Leung TW; Mo FK; Johnson PJ
    Anticancer Drugs; 2002 Jul; 13(6):655-62. PubMed ID: 12172512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel in combination with epirubicin in metastatic breast cancer: pharmacokinetic interactions.
    Ceruti M; Tagini V; Recalenda V; Arpicco S; Cattel L; Airoldi M; Bumma C
    Farmaco; 1999; 54(11-12):733-9. PubMed ID: 10668172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
    Kwasny W; Kornek G; Haider K; Valencak J; Ulrich-Pur H; Penz M; Lang F; Depisch D; Scheithauer W
    Breast Cancer Res Treat; 2000 Oct; 63(3):235-41. PubMed ID: 11110057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
    Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
    Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
    Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
    J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.
    Crivellari D; Pagani O; Veronesi A; Lombardi D; Nolè F; Thürlimann B; Hess D; Borner M; Bauer J; Martinelli G; Graffeo R; Sessa C; Goldhirsch A;
    Ann Oncol; 2001 Mar; 12(3):353-6. PubMed ID: 11332148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.